Herceptin’s revenue trends
In 3Q17, Roche’s (RHHBY) Herceptin generated revenues of 1.7 billion Swiss francs, which is a 5% fall on a quarter-over-quarter (or QoQ) basis. Herceptin revenues remained flat compared to 3Q16. In 3Q17, in the US, European, and Japanese markets, Herceptin generated revenues of 627 million Swiss francs, 524 million Swiss francs, and 73 million Swiss francs, respectively. In 3Q17, in the US and European markets, Herceptin witnessed a ~3% growth and a 2% fall on a year-over-year (or YoY) basis.
Perjeta’s revenue trends
In 3Q17, Roche’s Perjeta generated revenues of 552 million Swiss francs, which reflected ~17% growth YoY and 2% growth QoQ. In 3Q17, in the US, European, and Japanese markets, Perjeta reported revenues of 249 million Swiss francs, 201 million Swiss francs, and 30 million Swiss francs, respectively, which reflected ~10%, ~20%, and ~22% growth, respectively, YoY.
In September 2017, the FDA (U.S. Food & Drug Administration) accepted Roche’s supplemental Biologics License Application (or sBLA) and established priority review for Perjeta in combination with Herceptin and chemotherapy (Perjeta-based regimen) for adjuvant treatment (post-surgical therapy) of individuals with HER2-positive (human epidermal growth factor receptor 2–positive) early breast cancer (or eBC).
Kadcyla’s revenue trends
In 3Q17, Kadcyla generated revenues of 228 million Swiss francs, which reflected ~10% growth on a YoY basis and 8% growth on a QoQ basis. In 3Q17, in the US, European, and Japanese markets, Kadcyla generated revenues of 83 million Swiss francs, 88 million Swiss francs, and 18 million Swiss francs, respectively, which is ~7%, ~2%, and ~2% growth, respectively, YoY.
Growth in sales of Roche’s breast cancer drugs could boost the share price of the Vanguard FTSE All-World ex-US ETF (VEU). Roche makes up ~0.71% of VEU’s total portfolio holdings. VEU invests 0.43% of its total portfolio holdings in Sanofi (SNY), Roche’s peer in the oncology drugs market.